A. V. Lebedeva

ORCID: 0000-0001-5881-1795
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Research Studies
  • Neuroendocrine Tumor Research Advances
  • Neuroblastoma Research and Treatments
  • Healthcare Systems and Public Health
  • Folate and B Vitamins Research
  • Cellular transport and secretion
  • Medicinal Plants and Bioactive Compounds
  • Sepsis Diagnosis and Treatment
  • Educational Innovations and Challenges
  • Growth Hormone and Insulin-like Growth Factors
  • Educational Technology and Assessment
  • Peptidase Inhibition and Analysis
  • Inflammatory Biomarkers in Disease Prognosis
  • Neutropenia and Cancer Infections
  • Human Health and Disease
  • Education and Professional Development
  • Educational Methods and Teacher Development
  • Open Education and E-Learning
  • Nutrition and Health in Aging
  • Innovative Educational Technologies
  • Neurological Disease Mechanisms and Treatments
  • Technology and Human Factors in Education and Health
  • Neurological Disorders and Treatments
  • Cancer Risks and Factors
  • Lung Cancer Treatments and Mutations

Ministry of Health of the Russian Federation
2014-2024

City Clinical Hospital
2014-2020

Botkin Hospital
2020

Pirogov Russian National Research Medical University
2014

Background. Assessing nutritional status at the start of treatment for patients with diffuse large B-cell lymphoma allows us to plan adequate accompanying in whom early support can improve results antitumor treatment. Aim. To assess prevalence deficiency, features usual diet energy and protein composition who are starting Materials methods. The study included 96 adult (m = 61), average age 38.9 ± 16.8 years, newly diagnosed various localization prevalence. Additional laboratory screening...

10.17650/1818-8346-2024-19-3-233-242 article EN cc-by Oncohematology 2024-09-03

For the first time in Russia a comparative study of chromogranin A (CgA) and B (CgB) neuroendocrine tumors (NETs) pancreas was performed. We examined 50 primary patients with pancreatic NETs 42 healthy people. The determination CgA CgB performed blood serum using standard enzyme-linked immunoassay test-systems (Chromogranin NEOLISA, Eurodiagnostica; Human Chromogranin B, USCN). levels significantly differed from control group. There found association between dissemination process, while...

10.33667/2078-5631-2020-8-26-28 article EN cc-by Medical alphabet 2020-06-16

Background. Infectious manifestations and sepsis are life-threatening complications in the course of complex therapy patients with cancer. The mortality rate can reach up to 30-50% if did not receive timely antibiotic treatment. However, infectious diseases biomarkers aid early diagnosis. Aim trial is compare for systemic inflammation (C-reactive protein, nitric oxide metabolites), (procalcitonin, presepsin), antioxidant defense oxidative damage (rate reduced oxidized forms glutathione)...

10.15690/onco.v3i4.1633 article EN Oncopediatrics 2016-01-01

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms from cells the diffuse neuroendocrine system. Chromogranin B (CgB) is an acidic protein granin family, which can be used to detect tumours nature. Analysis levels and evaluation diagnostic efficiency CgB in blood serum patients with NETs various localizations. Patients (n=121) without specific treatment were examined. In study presented next localizations: 74 - pancreas, 20 stomach, 12 large intestine, 15 other localizations...

10.51620/0869-2084-2022-67-8-440-443 article EN Russian Clinical Laboratory Diagnostics 2022-09-09

The paper considers the basic mechanisms for occurrence of asthenic syndrome in chronic neurological diseases. It shows significance this problem nosological entities, such as stroke sequels, multiple sclerosis, and Parkinson’s disease. main asthenia diagnostic scales are described. Possible therapeutic strategies aimed at reducing degree patients also presented.

10.17650/1818-8338-2013-2-64-72 article EN DOAJ (DOAJ: Directory of Open Access Journals) 2014-07-01

Homocysteine is a specific marker of methotrexate toxicity and reflects the degree folate metabolism suppression during high-dose therapy. itself has also toxic effect on organism. Biochemically homocysteine associated with polyamines because S-adenosylmethionine common precursor in biosynthesis homocysteine. These ways can be seen as interrelated, mutual influencing competing. Polyamines are essential molecules for proliferation processes all living cells, including cancer cells. The levels...

10.15690/onco.v4i1.1685 article EN cc-by Oncopediatrics 2017-01-01

Any systems of support for making medical decisions should be considered, first all, as technologies helping to improve the process providing care patient. Experience shows that these can significantly quality diagnosis and treatment many socially significant diseases.

10.46594/2687-0037_2020_3_1234 article EN Virtual Technologies in Medicine 2020-01-01

Introduction . Carcinoid syndrome is the most common functional in patients with neuroendocrine tumors. More than 40 biochemical factors are responsible for manifestation of carcinoid syndrome, among which serotonin important. The study markers and associated heart disease an important aim laboratory examination tumors patients. Aim Analysis levels diagnostic efficiency evaluation chromogranin A (CgA), serotonin, pro-brain natriuretic peptide (proBNP) platelet-derived growth factor (PDGF-BB)...

10.17650/2313-805x-2022-9-4-71-77 article EN cc-by Advances in molecular oncology 2022-12-17

Introduction. Immunoenzyme assay of biochemical markers is one the most important methods for examination pa- tients with neuroendocrine tumors (NETs). Along generally accepted NET marker chromogranin A (CgA), another member granin family, B (CgB), can serve as a complementary marker. Objectives. Analysis CgB an additional to CgA in blood serum patients gastric and pancreatic tumors. Materials methods. We examined 79 gastic ( n = 14) pancretic 65) NETS, 42 particularly healthy people, who...

10.17650/2313-805x-2021-8-3-8-13 article EN cc-by Advances in molecular oncology 2021-11-02
Coming Soon ...